Scaranti, Mariana
Cojocaru, Elena http://orcid.org/0000-0002-7226-9784
Banerjee, Susana
Banerji, Udai http://orcid.org/0000-0003-1503-3123
Article History
Accepted: 3 February 2020
First Online: 9 March 2020
Competing interests
: S.B. has received institutional research grants from AstraZeneca. She has received honoraria for advisory board membership, lectures and/or reimbursement from AstraZeneca, Clovis, Gamamabs, Immunogen, Merck Serono, Nucana, Roche, Seattle Genetics, and Tesaro. She has acted as an unpaid Trial Steering Committee Member for the FORWARD I trial (Immunogen) and the Local Principal Investigator for the phase I ONX-0801/CT900 trial. U.B. has received institutional research funding for the investigator-initiated trial of ONX-0801 (discussed in the article) from BTG International and ONYX Pharmaceuticals and institutional funding for other investigator-initiated trials from AstraZeneca, Chugai and Verastem. He is a full-time employee of the (UK) Institute of Cancer Research, which is involved in the development of inhibitors of PI3K, HSP90, AKT, HDAC, ROCK, RAF, CHK1, MPS-1, HSF1 and FRα-targeted drugs including CT900. He has received honoraria from Astellas, Astex, Boehringer–Ingelheim, Eli Lilly, Janssen, Karus Therapeutics, Novartis, Phoenix Solutions and Vernalis. He has acted as an unpaid adviser to Sierra Oncology. E.C. and M.S. declare no competing interests.